The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kuvaev R.O.

Pirogov Russian National Research Medical University;
Regional Clinical Oncological Hospital

Not sour!

Authors:

Kuvaev R.O.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2025;(4): 80‑86

Read: 463 times

To cite this article:

Kuvaev RO. Not sour! Non Nocere. New Therapeutic Journal. 2025;(4):80‑86. (In Russ.)

References:

  1. Shanika LGT, Reynolds A, Pattison S, Braund R. Proton pump inhibitor use: systematic review of global trends and practices. Eur J Clin Pharmacol. 2023 Sep;79(9):1159-1172. https://doi.org/10.1007/s00228-023-03534-z
  2. Hu X, You X, Sun X, Lv J, Wu Y, Liu Q, et al. Off label use of proton pump inhibitors and economic burden in Chinese population: a retrospective analysis using claims database. Value in Health. 2018;21:S82–S83.  https://doi.org/10.1016/j.jval.2018.04.560
  3. Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Curr Opin Gastroenterol. 2017 Nov;33(6):430-438.  https://doi.org/10.1097/MOG.0000000000000392
  4. Maev I. V., Andreev D. N., Zaborovsky A. V. Fundamental bases of acid production in the stomach. Medical Council. 2018;(3):7-14.  https://doi.org/10.21518/2079-701X-2018-3-7-14
  5. Ivashkin V.T., Lopina O.D. Cellular mechanisms of hydrochloric acid secretion and proton pump inhibitors. In the book: Prevention and treatment of chronic diseases of the upper gastrointestinal tract / Edited by Acad. RAMS V. T. Ivashkin. 2nd edition, revision and additions. Moscow: MEDpress-Inform, 2013.
  6. Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol. 2010 Apr;45(4):389-394.  https://doi.org/10.3109/00365520903477348
  7. Isakov V.A. Therapy of acid-dependent diseases with proton pump inhibitors in questions and answers. Consilium Medicum. 2006;8(7):21-26. 
  8. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51 Suppl 1:59-67.  https://doi.org/10.1159/000200917
  9. Chen JW, Vela MF, Peterson KA, Carlson DA. AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review. Clin Gastroenterol Hepatol. 2023 Jun;21(6):1414-1421.e3.  https://doi.org/10.1016/j.cgh.2023.01.040
  10. Elliott SL, Ferris RJ, Giraud AS, Cook GA, Skeljo MV, Yeomans ND. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol. 1996 May;23(5):432-434.  https://doi.org/10.1111/j.1440-1681.1996.tb02754.x
  11. Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Pract Res Clin Gastroenterol. 2001 Jun;15(3):413-431.  https://doi.org/10.1053/bega.2001.0188
  12. De Francesco V, Ierardi E, Hassan C, Zullo A. Helicobacter pylori therapy: Present and future. World J Gastrointest Pharmacol Ther. 2012;3(4):68-73.  https://doi.org/10.4292/wjgpt.v3.i4.68
  13. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997 Jan;39(1):5-12.  https://doi.org/10.1093/jac/39.1.5
  14. Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Ikuma M, Ishizaki T, Hishida A. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007 Aug;12(4):317-323.  https://doi.org/10.1111/j.1523-5378.2007.00508.x
  15. Akazawa Y, Fukuda D, Fukuda Y. Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence. Therap Adv Gastroenterol. 2016 Nov;9(6):845-852.  https://doi.org/10.1177/1756283X16668093
  16. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016 Sep;65(9):1439-1446. https://doi.org/10.1136/gutjnl2015-311304
  17. Chaimoff C, Creter D, Djaldetti M. The effect of pH on platelet and coagulation factor activities. Am J Surg. 1978 Aug;136(2):257-259.  https://doi.org/10.1016/0002-9610(78)90241-6
  18. Green FW Jr, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology. 1978 Jan;74(1):38-43. 
  19. Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse Effects Associated with Proton Pump Inhibitor Use. Cureus. 2021 Jan 18;13(1):e12759. https://doi.org/10.7759/cureus.12759
  20. Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. 2017 Jul;153(1):35-48.  https://doi.org/10.1053/j.gastro.2017.04.047
  21. Cheung KS, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Therap Adv Gastroenterol. 2019 Mar 11;12:1756284819834511. https://doi.org/10.1177/1756284819834511
  22. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009 Jan;65(1):19-31.  https://doi.org/10.1007/s00228-008-0576-5
  23. Bordin D.S. Safety of treatment as a criterion for the choice of proton pump inhibitor in a patient with gastroesophageal reflux disease. Consilium Medicum. 2010;12(8):77-
  24. Helgadottir H, Bjornsson ES. Problems Associated with Deprescribing of Proton Pump Inhibitors. Int J Mol Sci. 2019 Nov 2;20(21):5469. . PMID: 31684070; PMCID: PMC6862638  https://doi.org/10.3390/ijms20215469
  25. Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. 2022 Apr;162(4):1334-1342. https://doi.org/10.1053/j.gastro.2021.12.247
  26. Maev I.V., Zaborovsky A.V., Tararina L.A., et al. Efficiency and Safety of Pantoprazol in Treatment of Patients with Acid Dependent Diseases in Russia: Multicenter Observe Research. Effective Pharmacotherapy. 2023;19(43):20-27.  https://doi.org/10.33978/2307-3586-2023-19-43-20-27

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.